PainChek Limited (ASX:PCK)

Market Cap	64.47M
Revenue (ttm)	3.03M
Net Income (ttm)	-8.17M
Shares Out	1.84B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,774,350
Average Volume	859,571
Open	0.0350
Previous Close	0.0350
Day's Range	0.0340 - 0.0380
52-Week Range	0.0240 - 0.0590
Beta	0.30
RSI	40.51
Earnings Date	Jul 31, 2025

About Intercept Pharmaceuticals

PainChek Limited develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. The company offers PainChek, which uses cameras in smartphones and tablets for a facial scan that is analyzed in real time using facial recognition software to indicate the presence of pain. It serves patients suffering with dementia and pre-verbal infants; and the aged care, disability, home care, hospital, and infant sectors. The company was formerly known as ePAT ...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Philip Daffas
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PCK

Financial Performance

In 2024, PainChek's revenue was 2.67 million, an increase of 36.61% compared to the previous year's 1.96 million. Losses were -8.31 million, 9.68% more than in 2023.